Eleva Biologics

Eleva Publishes Evidence of Immunomodulation and Neuroprotection Using its Factor H Biological Therapy in Preclinical Dry AMD Study

Eleva confirms dry AMD as second indication for proprietary Factor H (CPV-104) program 15 April 2025 -- Freiburg im Breisgau, Germany -- Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the publication of new data on its lead pipeline asset Factor H (CPV-104) in the...

Eleva Receives Orphan Drug Designation in Europe for Proprietary Factor H Therapy in C3 Glomerulopathy (C3G)

3 July 2024 -- Freiburg Im Breisgau, Germany -- Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today that the European Commission (EC) has granted the Orphan Drug Designation (ODD) for Factor H (CPV-104), the company’s recombinant version of human complement Factor H, to treat C3 Glomerulopathy (C3G). Eleva...
Hans-Bunte-Str. 19 79108 Freiburg Germany

+49 (0)761 470990